Gómez Sara, Gamazo Carlos, San Roman Beatriz, Vauthier Christine, Ferrer Marta, Irachel Juan M
Adjuvant Unit, Department of Pharmaceutical Technology and Microbiology, University of Navarra, 31080 Pamplona, Spain.
J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):3283-9. doi: 10.1166/jnn.2006.471.
The adjuvant capacity of a novel vaccine vector "Gantrez-nanoparticles" (NP) towards coated or encapsulated ovalbumin (OVA) was investigated. OVA nanoparticles were prepared by a solvent displacement method previously described. The protein was incorporated during the manufacturing process (OVA-encapsulated nanoparticles) or after the preparation (OVA-coated nanoparticles). The mean size of the different nanoparticle formulations was lower than 300 nm, and the OVA content ranged approximately from 67 microg/mg nanoparticles (for OVA-coated nanoparticles) to 30 microg/mg nanoparticles (for OVA-encapsulated nanoparticles). All the OVA-NP formulations were capable of amplifying the antibodies titres (IgG1 and IgG2a) in mice after a single subcutaneous inoculation with respect free OVA or OVA adsorbed to Alum. Furthermore, the elicited response was, for some formulations, predominantly Th1 subtype. Thus, the formulation that contained mainly the antigen inside, and with a low concentration of cross-linking agent, displayed the best potential to induce a Th1 response after 35 days post-immunisation. These results are highly suggestive for the use of Gantrez nanoparticles as an efficient antigen delivery system, especially when a long lasting Th1 cytokine response is required.
研究了新型疫苗载体“甘胆酯纳米颗粒”（NP）对包被或包裹卵清蛋白（OVA）的佐剂能力。OVA纳米颗粒通过先前描述的溶剂置换法制备。蛋白质在制造过程中掺入（OVA包裹的纳米颗粒）或在制备后掺入（OVA包被的纳米颗粒）。不同纳米颗粒制剂的平均尺寸小于300nm，OVA含量范围约为67μg/mg纳米颗粒（对于OVA包被的纳米颗粒）至30μg/mg纳米颗粒（对于OVA包裹的纳米颗粒）。与游离OVA或吸附于明矾的OVA相比，所有OVA-NP制剂在单次皮下接种后均能提高小鼠的抗体滴度（IgG1和IgG2a）。此外，对于某些制剂，引发的反应主要是Th1亚型。因此，主要在内部含有抗原且交联剂浓度低的制剂在免疫后35天显示出诱导Th1反应的最佳潜力。这些结果强烈表明甘胆酯纳米颗粒可作为一种有效的抗原递送系统，特别是当需要持久的Th1细胞因子反应时。
